Literature DB >> 25644395

Does the average drug exposure in pregnant women affect pregnancy outcome? A comparison of two approaches to estimate the baseline risks of adverse pregnancy outcome.

Evelin Wacker1, Ana Navarro, Reinhard Meister, Stephanie Padberg, Corinna Weber-Schoendorfer, Christof Schaefer.   

Abstract

PURPOSE: The results of observational cohort studies on drug effects on pregnancy outcome may depend among others on suitable comparison cohorts. The aim of this investigation was to compare two distinct definitions of maternal exposure status for comparison cohorts.
METHODS: We performed an observational cohort study of prospectively ascertained pregnant women who spontaneously contacted the Teratology Information Service (TIS) Berlin for drug risk consultation. The only exclusion criteria were exposures to established teratogens and/or fetotoxicants. Pregnancy outcomes of 3250 women with this "average drug exposure" were compared with 546 non-exposed or insignificantly exposed pregnancies.
RESULTS: Neither the rate of major birth defects (3.0%; aOR 1.62; 95% CI 0.8-3.3) nor the risk of spontaneous abortion (16.0%; aHR 1.20; 95% CI 0.8-1.7) was significantly increased after average drug exposure, whereas the rate of electively terminated pregnancies was higher (11.1%; aHR 2.05; 95% CI 1.2-3.4). There were no differences in the risk of preterm birth (9.9%; aOR 1.38; 95% CI 0.9-2.0) and infants' birth weight (p = 0.60).
CONCLUSIONS: This study does not provide evidence for an increased risk of adverse pregnancy outcome after average drug exposure during pregnancy. Therefore, comparison cohorts with average drug exposure are appropriate for studies on potential teratogens or fetotoxicants based on observational data collected by TIS.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  comparison cohort; drug safety; observational cohort study; pharmacoepidemiology; pregnancy; prospective

Mesh:

Year:  2015        PMID: 25644395     DOI: 10.1002/pds.3744

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  4 in total

1.  Drug safety in pregnancy: the German Embryotox institute.

Authors:  Katarina Dathe; Christof Schaefer
Journal:  Eur J Clin Pharmacol       Date:  2017-10-24       Impact factor: 2.953

2.  Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study.

Authors:  Corinna Weber-Schoendorfer; Marc Oppermann; Evelin Wacker; Nathalie Bernard; Delphine Beghin; Benedikte Cuppers-Maarschalkerweerd; Jonathan L Richardson; Laura E Rothuizen; Alessandra Pistelli; Heli Malm; Georgios Eleftheriou; Debra Kennedy; Mine Kadioglu Duman; Reinhard Meister; Christof Schaefer
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

Review 3.  Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations.

Authors:  Yang Mao-Draayer; Sandra Thiel; Elizabeth A Mills; Tanuja Chitnis; Michelle Fabian; Ilana Katz Sand; M Isabel Leite; Sven Jarius; Kerstin Hellwig
Journal:  Nat Rev Neurol       Date:  2020-02-20       Impact factor: 42.937

4.  Adverse drug reactions in high-risk pregnant women: A prospective study.

Authors:  Alfredo Dias de Oliveira-Filho; Antonio Emanuel Soares Vieira; Roberta Cruz da Silva; Sabrina Joany Felizardo Neves; Thiago Antonio Barros Gama; Ryane Vieira Lima; Wlisses Ramon Oliveira; Júlia Maria de Gonçalves Dias
Journal:  Saudi Pharm J       Date:  2017-02-02       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.